Developing Personalized Medicine for Lung Cancer. The University of Texas SPORE in Lung Cancer represents a unique collaboration between the University of Texas Southwestern Medical Center (UTSW) and the University of Texas MD Anderson Cancer Center (MDACC) both of which have outstanding Strengths in lung cancer translational research. The overarching goal of the SPORE is to develop new experimental paradigms leading to personalized medicine approaches for lung cancer based on a molecular understanding of lung cancers in individual patients, and using this information to select the therapy ("personalize") of each NSCLC patient's treatment. The SPORE builds on a 16 year productive history and incorporates recent advances made by SPORE investigators and others in lung cancer genomics, as well as important new advances in identifying and understanding lung cancer "acquired vulnerabilities" (synthetic lethalities). Together this will provide a more complete mechanistic understanding of the molecular findings so they can be applied to patients. These advances include novel approaches to functionally classify lung cancer by determining precisely the acquired vulnerabilities of each tumor, studying new molecular classifications of NSCLC related mRNA expression and DNA mutational "clades" and their functional characteristics, developing tools for CLIA certifiable molecular classification tests, preclinical model systems for testing the value of these new classification schemes, and a large legacy of molecular and clinical annotated datasets of lung cancers for retrospective analyses. The SPORE is composed of 4 projects: #1. Personalized medicine for NSCLC based on molecular portraits/"clades";#2. Epidemiologic study of the role miR polymorphisms for predicting risk of lung cancer development and recurrence;#3. Therapeutic targeting of PI3K and MEK in mutant KRAS driven lung cancer for radiosensitization and blocking metastases;and #4. Therapeutic targeting of telomerase dependence on maintaining telomeres in lung cancer stem cells. In addition there are three cores: A. Administrative (including patient advocates), B. Molecular pathology, and C. Biostatistics-bioinformatics. The SPORE has some of the leading lung cancer translational investigators in the world in addition to a multidisciplinry group of clinical and laboratory scientists as well as a cadre of experienced patient advocates. The projects planned in this SPORE application will provide a new functional classification of lung cancer therapeutics, and the opportunity to change the face of NSCLC therapy.

Public Health Relevance

This SPORE in Lung Cancer assembles a multidisciplinary team of clinical and basic scientists from two leading lung cancer research institutions (UTSW and MDACC) to develop new ways to diagnose and treat lung cancer based on a rationale understanding of its molecular underpinnings and thus provide new personalized medicine for lung cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA070907-16A1
Application #
8738108
Study Section
Special Emphasis Panel (ZCA1-RPRB-C (M1))
Program Officer
Ujhazy, Peter
Project Start
1996-09-30
Project End
2019-08-31
Budget Start
2014-09-23
Budget End
2015-08-31
Support Year
16
Fiscal Year
2014
Total Cost
$2,161,999
Indirect Cost
$433,224
Name
University of Texas Sw Medical Center Dallas
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
800771545
City
Dallas
State
TX
Country
United States
Zip Code
75390
Wen, Chi-Pang; Zhang, Fanmao; Liang, Dong et al. (2015) The ability of bilirubin in identifying smokers with higher risk of lung cancer: a large cohort study in conjunction with global metabolomic profiling. Clin Cancer Res 21:193-200
Chiappori, A A; Kolevska, T; Spigel, D R et al. (2015) A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small-cell lung cancer. Ann Oncol 26:354-62
Mender, Ilgen; Gryaznov, Sergei; Dikmen, Z Gunnur et al. (2015) Induction of telomere dysfunction mediated by the telomerase substrate precursor 6-thio-2'-deoxyguanosine. Cancer Discov 5:82-95
Kim, Eric S; Ye, Yuanqing; Vaporciyan, Ara A et al. (2015) Telomere length and recurrence risk after curative resection in patients with early-stage non-small-cell lung cancer: a prospective cohort study. J Thorac Oncol 10:302-8
Ludlow, Andrew T; Robin, Jerome D; Sayed, Mohammed et al. (2014) Quantitative telomerase enzyme activity determination using droplet digital PCR with single cell resolution. Nucleic Acids Res 42:e104
Fujimoto, Junya; Wistuba, Ignacio I (2014) Current concepts on the molecular pathology of non-small cell lung carcinoma. Semin Diagn Pathol 31:306-13
Yang, Yanan; Ahn, Young-Ho; Chen, Yulong et al. (2014) ZEB1 sensitizes lung adenocarcinoma to metastasis suppression by PI3K antagonism. J Clin Invest 124:2696-708
Lin, Steven H; Wang, Jing; Saintigny, Pierre et al. (2014) Genes suppressed by DNA methylation in non-small cell lung cancer reveal the epigenetics of epithelial-mesenchymal transition. BMC Genomics 15:1079
Osborne, Jihan K; Guerra, Marcy L; Gonzales, Joshua X et al. (2014) NeuroD1 mediates nicotine-induced migration and invasion via regulation of the nicotinic acetylcholine receptor subunits in a subset of neural and neuroendocrine carcinomas. Mol Biol Cell 25:1782-92
Holohan, Brody; Wright, Woodring E; Shay, Jerry W (2014) Cell biology of disease: Telomeropathies: an emerging spectrum disorder. J Cell Biol 205:289-99

Showing the most recent 10 out of 647 publications